Innoviva (INVA) Stock Overview
Operates as a biopharmaceutical company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
INVA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Innoviva, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.20 |
| 52 Week High | US$25.15 |
| 52 Week Low | US$16.52 |
| Beta | 0.40 |
| 1 Month Change | 7.99% |
| 3 Month Change | 23.60% |
| 1 Year Change | 41.52% |
| 3 Year Change | 98.36% |
| 5 Year Change | 103.53% |
| Change since IPO | 33.63% |
Recent News & Updates
Recent updates
Innoviva's (NASDAQ:INVA) Solid Profits Have Weak Fundamentals
Nov 13
Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The Market
Nov 12We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Sep 11Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 09Innoviva, Inc.'s (NASDAQ:INVA) Low P/S No Reason For Excitement
Jun 23Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma
Jun 08Innoviva: Underappreciated Strength In Hospital Therapeutics
Feb 23Innoviva, Inc.'s (NASDAQ:INVA) Popularity With Investors Is Under Threat From Overpricing
Dec 19Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price
Jul 26Innoviva: Potentially Overvalued
Jun 21Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems
May 21Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Feb 05Is Innoviva (NASDAQ:INVA) A Risky Investment?
Nov 04Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly
Mar 02Innoviva Stock? Not Yet. Short Puts? Definitely.
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Jun 16Continuing To Avoid Innoviva Inc.
Jun 07We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Mar 04Taking Innoviva Winnings Off The Table, Again
Feb 21Innoviva Inc.: Short Puts Are Compelling
Jan 15Is Innoviva (NASDAQ:INVA) A Risky Investment?
Oct 19Taking Profits In Innoviva Inc.
Oct 16These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Mar 30Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 04Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?
Jan 15These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Dec 25
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?
Dec 04Shareholder Returns
| INVA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.3% | 0.7% | 3.4% |
| 1Y | 41.5% | 43.5% | 29.7% |
Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: INVA exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| INVA volatility | |
|---|---|
| INVA Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: INVA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INVA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 159 | Pavel Raifeld | www.inva.com |
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.
Innoviva, Inc. Fundamentals Summary
| INVA fundamental statistics | |
|---|---|
| Market cap | US$1.75b |
| Earnings (TTM) | US$271.17m |
| Revenue (TTM) | US$411.33m |
Is INVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INVA income statement (TTM) | |
|---|---|
| Revenue | US$411.33m |
| Cost of Revenue | US$103.09m |
| Gross Profit | US$308.23m |
| Other Expenses | US$37.07m |
| Earnings | US$271.17m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.66 |
| Gross Margin | 74.94% |
| Net Profit Margin | 65.92% |
| Debt/Equity Ratio | 27.3% |
How did INVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 09:02 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innoviva, Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jon Langenfeld | Baird |
| James Birchenough | Barclays |
| Patrick Trucchio | Berenberg |